|
|
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Roch Houot
,
Tony Marchand
,
Nathalie Dhédin
,
Willy Lescaut
,
Anne Thiebaut-Bertrand
et al.
Journal articles
hal-01517054v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Immune and Cell Therapy in Non-Hodgkin Lymphoma
Reid W. Merryman
,
Roch Houot
,
Philippe Armand
,
Caron Jacobson
Journal articles
hal-02890214v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Reid Merryman
,
Luca Castagna
,
Laura Giordano
,
Vincent Ho
,
Paolo Corradini
et al.
Journal articles
hal-03229516v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Early F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab
Aiping Chen
,
Fatima-Zohra Mokrane
,
Lawrence Schwartz
,
Franck Morschhauser
,
Apasia Stamatoullas
et al.
Journal articles
hal-02364994v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Chimeric antigen receptor (CAR) T-cells on the march from diffuse large B-cell lymphoma to mantle cell lymphoma
Roch Houot
,
Philippe Armand
,
Caron A Jacobson
Journal articles
hal-02569416v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Roch Houot
,
Ronald Levy
,
Guillaume Cartron
,
Philippe Armand
Journal articles
hal-02929021v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population
Samuel Vic
,
Jean Lemoine
,
Philippe Armand
,
François Lemonnier
,
Roch Houot
et al.
Journal articles
hal-04098893v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|